Ipsen : Q4 2019 sales and FY 2019 underlying operating profit in line – 2022 guidance reduced – TP lowered to € 69.4 (vs € 83.3)
>Satisfactory 2019 but in line – 2022 guidance reduced by >12% - Q4 sales were up 16.1% to € 701.9m and +16.2% at constant forex. For the full year, sales totaled € 2,576.2m (+15.8% and +14.8% at constant forex – Consensus: € 2,559m est.). Underlying operating profit was € 782.6m, i.e. 30.4% of sales (consensus: € 778m est.). The halt of the palovarotene programme has resulted in an impairment loss of € 669m before The corporate tax. Net profit totaled -€ 50m. With re...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.